The cytotoxic activity of the synthesized compounds was evaluated against MCF-7 breast cancer cells, revealing IC50 values of 29.44 μM for PZ-9 and 17.35 μM for PZ-11, compared to 6.45 μM for the reference drug vincristine...PZ-11 is a promising TZD-based anticancer drug candidate against breast cancer cells, as determined by computational and experimental analysis. However, further validation is required through in vivo analysis to support these findings.

P=N/A, N=786, Completed, Boston Medical Center | Active, not recruiting --> Completed

Concurrent methotrexate use was found to exacerbate VCR-induced neurotoxicity. VCR-induced neurotoxicity remains a significant challenge in ALL therapy. Standardized neurotoxicity assessment tools and prospective studies are needed to improve early detection and optimize management strategies, ultimately balancing treatment efficacy with minimizing neurological morbidity.

Unlike STD, which partially and transiently reduced stemness markers, mCHT achieved sustained suppression, indicating preferential targeting of therapy-resistant CSCs. These results indicate mCHT as a promising strategy for specifically aiming at the CSC-like compartment in TNBC, underscoring a therapeutic approach that reprograms key epigenetic networks and overcomes resistance to treatment.

The most frequently combined chemotherapy was vinorelbine (83/90,92.2%). The most frequently concomitant targeted drug was pyrotinib (70/90,77.8%)...Inetetamab offers a promising option and a manageable safety profile for HER2-positive MBC who pretreated with multiple-line therapies. Meanwhile, inetetamab plus small-molecule TKIs regimens shows good anti-tumor efficacy for MBC with brain metastases, which deserves further validation in a larger group trial.

SCHEMBL4796824, a BPR0L075 derivative with antitumor properties, targets tubulin's colchicine binding site and induces DNA damage response in ovarian cancer...Notably, these effects were more pronounced in c-MYC amplified SK-OV-3 cells. In summary, SCHEMBL4796824 disrupts the canonical Wnt/β-catenin signaling, inducing DNA damage, and inhibits the Wnt/β-catenin/c-MYC axis, triggering cellular senescence in a pathway-dependent manner, hinting at a novel therapeutic approach.

Early relapse suggested the aggressive nature of the tumor, requiring chemotherapy with VAC (vincristine, actinomycin D, and cyclophosphamide). This case highlights the importance of early diagnosis, and the urgent need for standardized therapeutic approaches to improve patient outcomes in ovarian RMS.

Both 3 μM and 10 μM H89 significantly reverses resistance to two ABCB1 substrate drugs (doxorubicin and vincristine) in HCT-8/V cells in a dose-dependent manner, with no such effect observed inHCT-8 cells. The combination of H89 with ABCB1 substrate drugs significantly reverses multidrug resistance in colorectal cancer. These findings provide a strong theoretical and experimental foundation for the development of novel MDR-reversing agents targeting ABCB1.

P=N/A, N=467, Completed, University Hospital, Clermont-Ferrand | Recruiting --> Completed | N=750 --> 467 | Trial completion date: Jul 2025 --> Nov 2025 | Trial primary completion date: Jul 2025 --> Nov 2025

While standard chemotherapies - vincristine, actinomycin D, and alkylating agents - are effective against localized disease, multidrug resistance (MDR) often leads to treatment failure in relapsed and metastatic RMS. Radiotherapy resistance is mediated through the DNA-PK-mTORC2-AKT axis, while drug transporters such as ABCB1 and SLC7A11, along with age-dependent CYP enzyme expression, affect drug bioavailability. Targeting these convergent mechanisms offers a promising therapeutic strategy to overcome resistance in FN-RMS.

P2, N=300, Active, not recruiting, Washington University School of Medicine | Enrolling by invitation --> Active, not recruiting

P3, N=70, Not yet recruiting, Ain Shams University